Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 6/20 | 1.00 |
| ▸ | NT5E | P21589 | 5/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.86 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.83 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21067537 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL14414858 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL29394370 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL15532186 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL16351400 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL24205127 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL4314227 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21724956 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL16674879 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL18351578 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | claimed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250382322-A1 | DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-3843714-B1 | CD73 INHIBITORS | ARCUS BIOSCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | NUVALENT INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114395005-A | Modulators of extracellular 5' -nucleotidase and uses thereof | 艾库斯生物科学有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022050230-A1 | COMPOSITION INHIBITING ACTIVATION OF ADENOSINE RECEPTOR | 学校法人埼玉医科大学 | 2022-03-10 | — | — | WO | disclosed |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220062313-A1 | SOLID FORMS OF A CD73 INHIBITOR AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| EP-3941481-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | Metro International Biotech, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ENPP1 7/4885NT5E 1/4885PLCG1 1251/4885 |
| US-20220062313-A1 | SOLID FORMS OF A CD73 INHIBITOR AND THE USE THEREOF | ENTPD5, ENTPD1, NT5C2 | ENPP1 10/4885NT5E 4/4885PLCG1 258/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ENPP1 7/4885NT5E 1/4885PLCG1 1251/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ENPP1 7/4885NT5E 1/4885PLCG1 1251/4885 |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | ENPP1 5/4885NT5E 3/4885PLCG1 309/4885 |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | ENPP1 705/4885NT5E 3163/4885PLCG1 2713/4885 |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP2F1, CYP11B2, CYP7B1 | ENPP1 2886/4885NT5E 4845/4885PLCG1 4248/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | ENPP1 596/4885NT5E 3064/4885PLCG1 2650/4885 |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | IL23R, IL17A, CA14 | ENPP1 909/4885NT5E 2748/4885PLCG1 3266/4885 |
| US-20250382322-A1 | DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) | NT5E, ENTPD5, ENTPD1 | ENPP1 10/4885NT5E 1/4885PLCG1 1431/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | ENPP1 12/4885NT5E 3/4885PLCG1 2225/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | ENPP1 10/4885NT5E 2/4885PLCG1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.